Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,661,030
  • Shares Outstanding, K 196,323
  • Annual Sales, $ 4,241 M
  • Annual Income, $ 32,610 K
  • EBIT $ 1,481 M
  • EBITDA $ 1,570 M
  • 60-Month Beta 0.82
  • Price/Sales 4.40
  • Price/Cash Flow 191.38
  • Price/Book 4.47

Options Overview Details

View History
  • Implied Volatility 38.17% (+3.04%)
  • Historical Volatility 37.46%
  • IV Percentile 51%
  • IV Rank 33.30%
  • IV High 64.77% on 10/31/25
  • IV Low 24.90% on 08/08/25
  • Expected Move (DTE 35) 8.53 (8.04%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 1,753
  • Volume Avg (30-Day) 911
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 21,524
  • Open Int (30-Day) 23,975
  • Expected Range 97.68 to 114.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.66
  • Number of Estimates 8
  • High Estimate 1.81
  • Low Estimate 1.53
  • Prior Year 1.09
  • Growth Rate Est. (year over year) +52.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
97.01 +9.48%
on 12/18/25
112.29 -5.41%
on 01/07/26
+9.18 (+9.46%)
since 12/16/25
3-Month
84.02 +26.41%
on 10/28/25
112.29 -5.41%
on 01/07/26
+18.90 (+21.65%)
since 10/16/25
52-Week
53.56 +98.30%
on 04/09/25
112.29 -5.41%
on 01/07/26
+33.74 (+46.56%)
since 01/16/25

Most Recent Stories

More News
2 Mid-Cap Stocks with Exciting Potential and 1 We Question

2 Mid-Cap Stocks with Exciting Potential and 1 We Question

CW : 663.84 (+0.48%)
KHC : 23.53 (-2.93%)
INCY : 106.21 (+0.92%)
Why Incyte (INCY) Stock Is Trading Up Today

Why Incyte (INCY) Stock Is Trading Up Today

INCY : 106.21 (+0.92%)
Earnings Preview: What To Expect From Incyte's Report

Incyte is scheduled to release its fourth-quarter results soon, with analysts projecting double-digit surge in its bottom line figure.

XLV : 155.74 (-0.78%)
$SPX : 6,940.01 (-0.06%)
INCY : 106.21 (+0.92%)
2 Cash-Heavy Stocks Worth Investigating and 1 Facing Challenges

2 Cash-Heavy Stocks Worth Investigating and 1 Facing Challenges

INCY : 106.21 (+0.92%)
PCTY : 140.10 (-1.09%)
CLOV : 2.54 (-3.05%)
Incyte (INCY) Stock Is Up, What You Need To Know

Incyte (INCY) Stock Is Up, What You Need To Know

INCY : 106.21 (+0.92%)
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma

- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi ® /Minjuvi ® ) and lenalidomide in addition to R-CHOP met its...

INCY : 106.21 (+0.92%)
2 Safe-and-Steady Stocks Worth Your Attention and 1 Facing Challenges

2 Safe-and-Steady Stocks Worth Your Attention and 1 Facing Challenges

MA : 539.49 (-0.58%)
STRA : 83.92 (-0.71%)
INCY : 106.21 (+0.92%)
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi ® (tafasitamab) in combination with rituximab and lenalidomide...

INCY : 106.21 (+0.92%)
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz ® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based...

INCY : 106.21 (+0.92%)
Incyte to Present at Upcoming Investor Conference

Incyte (Nasdaq:INCY) announced today that it will present at the 44 th Annual J. P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 am (PST). The presentation...

INCY : 106.21 (+0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 112.00
2nd Resistance Point 110.29
1st Resistance Point 108.25
Last Price 106.21
1st Support Level 104.50
2nd Support Level 102.79
3rd Support Level 100.75

See More

52-Week High 112.29
Last Price 106.21
Fibonacci 61.8% 89.86
Fibonacci 50% 82.93
Fibonacci 38.2% 75.99
52-Week Low 53.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar